Observational studyBMJ (Clinical research ed.)2020
Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study.
Observational study in BMJ (Clinical research ed.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 6 registered trials, which are not on this map. Cited by 1,941 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Case Fatalities in Hospitalised COVID-19 Patients in the UK: An ISARIC Study
An Evaluation of a Synbiotic Formula for Symptom Improvement in Hospitalised Patients With COVID-19 Infection
Clinical Characteristics and Outcomes of Patients With COVID-19 on Mechanical Ventilation in Argentina: a Prospective, Multicenter Cohort Study
Evaluation of a Synbiotic Formula in Patient With COVID-19
Intensive Dose Tinzaparin in Hospitalized COVID19 Patients
DYNamic Assessment of Multi Organ Level Dysfunction in Patients Recovering From Covid-19
Who cites it
1,941 citing papers in PubMed, 6 syntheses or guidelines pooled it, 3,617 citations in OpenAlex.
- Prevalence and duration of common symptoms in people with long COVID: a systematic review and meta-analysis.Journal of global health · 2025Pooled it
- Transition of care interventions to manage severe COVID-19 in the ambulatory setting: a systematic review.Internal and emergency medicine · 2024Pooled it
- Obesity and mortality in patients with COVID-19: A meta-analysis of prospective studies.Asia Pacific journal of clinical nutrition · 2024Pooled it
- Effectiveness of azvudine in reducing mortality of COVID-19 patients: a systematic review and meta-analysis.Virology journal · 2024Pooled it
- Meta-analysis of the serum/plasma proteome identifies significant associations between COVID-19 with Alzheimer's/Parkinson's diseases.Journal of neurovirology · 2024Pooled it
- Lung Ultrasound Score in COVID-19 Patients Correlates with POThe western journal of emergency medicine · 2024Pooled it
- Levels of circulating kidney injury markers and IL-10 identify non-critically ill patients with COVID-19 at risk of death.JCI insight · 2026Trial
- Alleviation of COVID-19 Symptoms and Reduction in Healthcare Utilization Among High-risk Patients Treated With Nirmatrelvir/Ritonavir (NMV/R): A Phase 3 Randomized Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Trial
- Safety and efficacy of oral administrated cepharanthine in non-hospitalized, asymptomatic or mild COVID-19 patients: a Double-blind, randomized, placebo-controlled trial : Author detials.Scientific reports · 2025Trial
- Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19.The New England journal of medicine · 2024Trial
- Novel subtypes of severe COVID-19 respiratory failure based on biological heterogeneity: a secondary analysis of a randomized controlled trial.Critical care (London, England) · 2024Trial
- Article
- Article
- Associated-Factor Studies in Biomedical Research: Foundations, Limitations, and Criteria for Appropriate Use.Epidemiologia (Basel, Switzerland) · 2026Review
- Article
- Effect of Long COVID-19: Self-Reported Questionnaires and Objective Olfactory and Gustatory Evaluations.Diseases (Basel, Switzerland) · 2026Article
- Six Years of COVID-19: Lessons from Epidemiology, Vaccination Campaigns, Clinical Risk Stratification, and Thromboembolic Surveillance.Vaccines · 2026Review
- Benchtop NMR as a clinical tool for acute respiratory illness: metabolic signatures associated with disease severity.Respiratory research · 2026Article
- Patient Characteristics and Healthcare Resource Use among Patients With COVID-19 Receiving Treatment with Nirmatrelvir/Ritonavir (PAXLOVID™) in the Kingdom of Saudi Arabia.Pulmonary therapy · 2026Article
- Adoptive T-cell therapies for persistent COVID-19 in immunocompromised patients: Comparison of IFN-γ virus-specific T-cell therapy and CD45RAGeroScience · 2026Article
1,881 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
26 authors at 12 institutions in 1 country.
Funding
Abstract
objectiveTo characterise the clinical features of patients admitted to hospital with coronavirus disease 2019 (covid-19) in the United Kingdom during the growth phase of the first wave of this outbreak who were enrolled in the International Severe Acute Respiratory and emerging Infections Consortium (ISARIC) World Health Organization (WHO) Clinical Characterisation Protocol UK (CCP-UK) study, and to explore risk factors associated with mortality in hospital.
designProspective observational cohort study with rapid data gathering and near real time analysis.
setting208 acute care hospitals in England, Wales, and Scotland between 6 February and 19 April 2020. A case report form developed by ISARIC and WHO was used to collect clinical data. A minimal follow-up time of two weeks (to 3 May 2020) allowed most patients to complete their hospital admission.
participants20 133 hospital inpatients with covid-19.
main outcome measuresAdmission to critical care (high dependency unit or intensive care unit) and mortality in hospital.
resultsThe median age of patients admitted to hospital with covid-19, or with a diagnosis of covid-19 made in hospital, was 73 years (interquartile range 58-82, range 0-104). More men were admitted than women (men 60%, n=12 068; women 40%, n=8065). The median duration of symptoms before admission was 4 days (interquartile range 1-8). The commonest comorbidities were chronic cardiac disease (31%, 5469/17 702), uncomplicated diabetes (21%, 3650/17 599), non-asthmatic chronic pulmonary disease (18%, 3128/17 634), and chronic kidney disease (16%, 2830/17 506); 23% (4161/18 525) had no reported major comorbidity. Overall, 41% (8199/20 133) of patients were discharged alive, 26% (5165/20 133) died, and 34% (6769/20 133) continued to receive care at the reporting date. 17% (3001/18 183) required admission to high dependency or intensive care units; of these, 28% (826/3001) were discharged alive, 32% (958/3001) died, and 41% (1217/3001) continued to receive care at the reporting date. Of those receiving mechanical ventilation, 17% (276/1658) were discharged alive, 37% (618/1658) died, and 46% (764/1658) remained in hospital. Increasing age, male sex, and comorbidities including chronic cardiac disease, non-asthmatic chronic pulmonary disease, chronic kidney disease, liver disease and obesity were associated with higher mortality in hospital.
conclusionsISARIC WHO CCP-UK is a large prospective cohort study of patients in hospital with covid-19. The study continues to enrol at the time of this report. In study participants, mortality was high, independent risk factors were increasing age, male sex, and chronic comorbidity, including obesity. This study has shown the importance of pandemic preparedness and the need to maintain readiness to launch research studies in response to outbreaks. STUDY REGISTRATION: ISRCTN66726260.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.